The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).
GREENSBORO, GA, UNITED STATES, March 4, 2026 /EINPresswire.com/ -- While CEOs at Davos pondered world problems over ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果